Precipio (PRPO) Q4 2024 earnings summary

Executive summary

• Achieved positive adjusted EBITDA and positive cash flow in Q4 2024, meeting break-even goals and signaling a shift from survival to growth mode.

• Revenue grew nearly 26% year-over-year in Q4 and 22% for the full year 2024, with a focus on converting pipeline into revenue.

• Pathology division consistently exceeded its $1.3M/month break-even point for two consecutive quarters, serving as a cash flow generator and growth platform.

• Product division maintained Q4 revenues at $700,000, with onboarding and regulatory challenges impacting timing but not long-term growth prospects.

• Strategic focus for 2025 includes accelerating growth, enhancing market visibility, and providing more consistent financial guidance.

Financial highlights

• Q4 2024 revenue increased nearly 26% compared to Q4 2023; full-year revenue up close to 22%.

• Achieved positive adjusted EBITDA and positive cash flow in Q4 2024.

• Pathology division exceeded break-even for two consecutive quarters.

• Product division Q4 revenue steady at $700,000, annualized run rate of $2.8M.

Outlook and guidance

• 2025 targets include organic growth in pathology to a $25M run rate and doubling product division run rate by year-end.

• Expecting more stable, predictable growth as customer base diversifies and onboarding processes improve.

• Plans to enhance investor relations and market visibility through conferences and increased analyst coverage.